PART I Overview We are a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases with the goal of improving patient outcomes. Our lead product candidate, cadisegliatin (TTP399) , is a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated in a Phase 3 clinical trial as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). The Cadisegliatin as Adjunct...
Q2 FY2026 — expected 2026-09-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-10 | 2025-12-31 | 0001641489-26-000010 | EDGAR | 68K words |
| 2025-03-20 | 2024-12-31 | 0001641489-25-000014 | EDGAR | — |
| 2024-03-13 | 2023-12-31 | 0001641489-24-000012 | EDGAR | — |
| 2023-03-06 | 2022-12-31 | 0001641489-23-000008 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001564590-22-012258 | EDGAR | — |
| 2021-02-24 | 2020-12-31 | 0001564590-21-008149 | EDGAR | — |
| 2020-02-21 | 2019-12-31 | 0001564590-20-005627 | EDGAR | — |
| 2019-02-26 | 2018-12-31 | 0001564590-19-004516 | EDGAR | — |
| 2018-02-27 | 2017-12-31 | 0001564590-18-003515 | EDGAR | — |
| 2017-02-24 | 2016-12-31 | 0001564590-17-002317 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001641489-26-000030 | EDGAR | — |
| 2025-11-06 | 2025-09-30 | 0001641489-25-000060 | EDGAR | 17K words |
| 2025-08-12 | 2025-06-30 | 0001641489-25-000053 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641489-25-000026 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001641489-24-000075 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001641489-24-000061 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001641489-24-000029 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001641489-23-000070 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001641489-23-000053 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001641489-23-000021 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001641489-22-000015 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001641489-22-000008 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001641489-26-000029 | EDGAR | — |
| 2026-03-10 | 0001641489-26-000012 | EDGAR | 3K words |
| 2026-03-10 | 0001641489-26-000011 | EDGAR | — |
| 2026-02-26 | 0001641489-26-000005 | EDGAR | — |
| 2026-02-02 | 0001641489-26-000002 | EDGAR | — |
| 2025-12-19 | 0001641489-25-000066 | EDGAR | — |
| 2025-11-06 | 0001641489-25-000058 | EDGAR | — |
| 2025-09-10 | 0001641489-25-000055 | EDGAR | — |
| 2025-09-02 | 0001193125-25-193486 | EDGAR | — |
| 2025-08-12 | 0001641489-25-000051 | EDGAR | — |
246 total filings indexed. 214 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001641489 |
| Ticker | VTVT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.vtvtherapeutics.com |
| Listed | 2015-07-30 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/VTVT (~200 tokens, structured JSON with cryptographic provenance)